GlobeNewswire - News from Maryland

CareFirst Launches “Better Together” Campaign Targeting Necessary COVID-19 Vaccine Adoption

Fri, 05 Feb 2021 16:35 GMT

Broad community education and mobilization effort includes new public health ad, expanded resources.

Broad community education and mobilization effort includes new public health ad, expanded resources.

The Community Financial Corporation Announces Record Results of 1.18% Return on Average Assets for Fourth Quarter 2020

Fri, 05 Feb 2021 14:28 GMT

Fourth Quarter and Full Year 2020 Highlights

Novavax und die Regierung der Schweiz geben eine Grundsatzvereinbarung zur Bereitstellung des COVID-19-Impfstoffes bekannt

Thu, 04 Feb 2021 22:05 GMT

Die Schweiz wird sechs Millionen Dosen des Impfstoffkandidaten NVX-CoV2373 von Novavax kaufen

Die Schweiz wird sechs Millionen Dosen des Impfstoffkandidaten NVX-CoV2373 von Novavax kaufen

Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization

Thu, 04 Feb 2021 21:05 GMT

GAITHERSBURG, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the start of the rolling review process for authorization of NVX-CoV2373, its COVID-19 vaccine, by multiple regulatory agencies. The reviews will continue while the company completes its pivotal Phase 3 trials in the United Kingdom (U.K.) and United States (U.S.) and through initial authorization for emergency use granted under country-specific regulations.

Liquidity Services Announces First Quarter Fiscal Year 2021 Financial Results

Thu, 04 Feb 2021 11:50 GMT

BETHESDA, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Liquidity Services (NASDAQ: LQDT; www.liquidityservices.com), the world’s largest B2B e-commerce marketplace for business and government surplus, today announced financial results for the first quarter fiscal year 2021 ended December 31, 2020. The Company's Q1-FY21 performance reflected continued customer adoption of our safe and effective e-commerce solutions across all business segments as businesses and governments seek proven digital solutions to stay competitive.

Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021

Thu, 04 Feb 2021 11:30 GMT

GAITHERSBURG, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 18, 2021 at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2020, recent business developments, financial outlook for full year 2021, and revenue guidance for the first quarter of 2021.

Novavax and Government of Switzerland Announce Agreement in Principle to Supply COVID-19 Vaccine

Thu, 04 Feb 2021 02:14 GMT

Switzerland to purchase six million doses of the Novavax vaccine candidate, NVX-CoV2373

Switzerland to purchase six million doses of the Novavax vaccine candidate, NVX-CoV2373

Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering

Thu, 04 Feb 2021 01:44 GMT

BOSTON and ROCKVILLE, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the pricing of its upsized initial public offering of 7,000,052 shares of common stock at a public offering price of $19.00 per share. The gross proceeds to Sensei from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sensei, are expected to be approximately $133.0 million. All of the shares are being offered by Sensei and are expected to begin trading on The Nasdaq Global Market on February 4, 2021 under the ticker symbol “SNSE.” In addition, Sensei has granted the underwriters a 30-day option to purchase up to an additional 1,050,007 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on February 8, 2021 subject to the satisfaction of customary closing conditions.

Inovalon Reports Fourth Quarter and Full Year 2020 Results

Wed, 03 Feb 2021 21:10 GMT

Fourth Quarter 2020 Highlights

Glen Burnie Bancorp Announces Fourth Quarter and Full Year 2020 Results

Wed, 03 Feb 2021 15:53 GMT

GLEN BURNIE, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Glen Burnie Bancorp (“Bancorp”) (NASDAQ: GLBZ), the bank holding company for The Bank of Glen Burnie (“Bank”), announced today a net income of $0.55 million, or $0.19 per basic and diluted common share for the three-month period ended December 31, 2020, as compared to net income of $0.54 million, or $0.19 per basic and diluted common share for the three-month period ended December 31, 2019.

Tenable to Participate in Upcoming Investor Conferences

Wed, 03 Feb 2021 14:00 GMT

COLUMBIA, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Tenable^?, the Cyber Exposure company, today announced that its Chairman and Chief Executive Officer, Amit Yoran, and Chief Financial Officer, Steve Vintz, are scheduled to attend upcoming investor conferences.

Complete Ethernet/Packet & Sonet/SDH Test & Analysis

Wed, 03 Feb 2021 12:17 GMT

(Wirespeed BERT to Protocol Analysis & Emulation up to 10 Gbps)

Tenable Announces Fourth Quarter and Full Year 2020 Financial Results

Tue, 02 Feb 2021 21:05 GMT

COLUMBIA, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Tenable Holdings, Inc. (“Tenable”) (Nasdaq: TENB), the Cyber Exposure company, today announced financial results for the quarter and year ended December 31, 2020.

Novavax Announces Memorandum of Understanding to Produce COVID-19 Vaccine Made in Canada

Tue, 02 Feb 2021 17:31 GMT

GAITHERSBURG, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced memorandum of understanding with the Canadian government to produce NVX-CoV2373, the Company’s protein-based vaccine candidate against COVID-19 in Canada.

Dr Yakov Kutsovsky Joins Pixelligent Technical Advisory Board

Tue, 02 Feb 2021 14:00 GMT

BALTIMORE, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pixelligent Technologies, whose PixClear? Designer Compounds? dramatically boost the efficiency and sustainability of consumer electronics and clean energy applications, today announced that it has named Dr. Yakov Kutsovsky to the Pixelligent Technical Advisory Board.

Capital Bancorp Announces Approval of New Stock Repurchase Program

Tue, 02 Feb 2021 13:45 GMT

ROCKVILLE, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Capital Bancorp, Inc. (the “Company”) (NASDAQ - CBNK), the holding company for Capital Bank, NA, today announced that its Board of Directors has approved a new stock repurchase program, which authorizes the Company to repurchase up to $7.5 million?of its outstanding common stock.?

Cerecor Announces Fast Track Designation for CERC-803 for the Treatment of Leukocyte Adhesion Deficiency Type II

Tue, 02 Feb 2021 12:00 GMT

ROCKVILLE, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CERC-803 for the treatment of Leukocyte Adhesion Deficiency Type II (LAD-II, also known as SLC35C1-CDG). The company remains on track to initiate a pivotal trial of CERC-803 in LAD-II in?the first half of 2021 and anticipates topline data in the second half of 2021.

Novavax to Present COVID-19 Vaccine Candidate Data at?New York Academy of Science

Tue, 02 Feb 2021 00:32 GMT

GAITHERSBURG, Md., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D, President of Research & Development, will present on NVX-CoV2373, the company’s COVID-19 vaccine, at The New York Academy of Science (NYAS) event, ‘The Quest for a COVID-19 Vaccine.’

Livanta Earns ISO Re-Certification

Mon, 01 Feb 2021 21:00 GMT

ANNAPOLIS JUNCTION, Md., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Livanta LLC (“Livanta”) announced that it has attained compliance with the International Organization for Standardization (ISO) 9001:2015 requirements for the third consecutive year, earning re-certification through December 2023. Extensive audits of the company’s operations were conducted most recently in November and December 2020, with re-certification officially confirmed on January 6, 2021. In the last three years (i.e., 2018-2020), Livanta’s ISO 9001 audits have resulted in zero negative findings. The company has continuously been recognized for developing and implementing best practices, activities, and processes to improve quality that go beyond the extensive ISO requirements. Livanta has maintained ISO 9001 certification for its quality management system since 2006.

SHELLY SPOETH JOINS ABT ASSOCIATES AS PRINCIPAL ASSOCIATE, COMMUNICATION AND BEHAVIOR CHANGE

Mon, 01 Feb 2021 15:00 GMT

Rockville, MD, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Abt ?Associates announced today that Shelly Spoeth has joined the company as a principal associate for communication and behavior change. She will serve as a strategic communication expert ?on projects for the Centers for Disease Control and Prevention (CDC), Health Resources and Services Administration, and the Office of Infectious Disease and HIV/AIDS Policy.